PureTech Announces Annual Results for Year Ended December 31, 2022

Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of $350.1 million,2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pipeline, with four clinical stage therapeutic candidates, including LYT-100 (ongoing registration-enabling trial in IPF), LYT-300 (Phase 2 ready Read the full article... The post PureTech Announces Annual Results for Year Ended December 31, 2022 first appeared on MJNews Network.
http://dlvr.it/SnCCnd

Comments

Popular posts from this blog

Ohio Board of Pharmacy Publishes Updated Patient & Caregiver Numbers for October 2021

KBS Sells TOBY Award-Winning 675,945 Square-Foot Class A Mixed-Use Property in Downtown Los Angeles, California for $104 Million